Endocrine Abstracts

ObjectiveThe exact risk of type 2 diabetes in women with polycystic ovary syndrome (PCOS) is unknown. It is also unclear if obesity independently increases the risk in this population. The aim of this study was to systematically review and synthesize the best available evidence regarding the association between PCOS and type 2 diabetes, stratified according to obesity status.MethodsA comprehensive search was ...

Single nucleotide polymorphisms in the glucocorticoid receptor (GR) gene influence tissue sensitivity of GR. Several studies have shown different effects of BclI GR polymorphism on body composition and metabolic parameters. The objective of this study was to explore the effect of BclI GR polymorphism on the body composition and glucose metabolism. Biochemical tests and hormonal evaluation were performed in 106 consecutive women with adrenal incidentalomas (AI...

Introduction: Chronic endogenous hypercortisolism in Cushing’s syndrome imposes a great clinical burden of comorbidities, some of which might persist even after disease remission. Our aim was to analyze factors that predict long-term comorbidities after surgical remission of Cushing’s disease (CD).Subjects and methods: We retrospectively analyzed 37 patents (91.9% females) aged 39.5±13.9 years (10-70) with diagnosed CD, treated in our inst...

Introduction: The diagnostic criteria of polycystic ovary syndrome (PCOS) are still under discussion and the hormonal parameters, including anti-Mullerian hormone range and hyperandrogenism, are not determined. Serum AMH level has been proposed as a surrogate marker for PCOM and could, therefore, be integrated in the diagnostic classifications for PCOS\. The aim of the present study was to characterize hormonal features of PCOS and to establish the most important hormonal para...

Introduction: Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy among women during reproductive age. PCOS cardinal manifestations include hyperandrogenism, oligo/anovulation, and/or polycystic ovarian morphology, and is closely linked to metabolic disorders such as obesity and insulin resistance (IR). It was observed that single-point insulin sensitivity estimator (SPISE) index is associated with metabolic abnormalities and could predict glucose regulation ...

Background: Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States. The MPOWERED trial (NCT02685709) showed that OOC were noninferior to injectable somatostatin receptor ligands (iSRLs; octreotide or lanreotide) in maintenance of biochemical control in patients previously responding to both treatments, as well as demonstrated improvements in patient-reported outcomes among patients receiving OOC.Objective:...

BackgroundMPOWERED, a large phase 3 trial, assessed maintenance of response to oral octreotide capsules (OOC; MYCAPSSA) compared to injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly who responded to OOC and iSRLs (octreotide or lanreotide). OOC were recently approved in the US for patients with acromegaly who responded to and tolerated iSRLs.MethodsEligibility criteria included age ...

BackgroundInjectable somatostatin receptor ligands (iSRLs) have been a mainstay in acromegaly treatment. Oral octreotide capsules (OOC; MYCAPSSA®) were recently approved in the USA. Results from the placebo-controlled CHIASMA OPTIMAL and open-label CH-ACM-01 studies showed an OOC safety profile consistent with that of iSRLs with no new or unexpected safety signals. Results of the MPOWERED trial have enabled a comparison of OOC safety and ...

BackgroundPatients with acromegaly may have high symptom burden. The phase 3 MPOWERED trial assessed control of acromegaly by oral octreotide capsules (OOC; MYCAPSSA®) in comparison to injectable somatostatin receptor ligands (iSRLs) in patients responding to both OOC and iSRLs. iSRLs have been first-line medical treatment for patients with acromegaly for decades. OOC are newly approved in the US for patients previously controlled on iSRL...

BackgroundOral octreotide capsules (OOC; MYCAPSSA®) are approved in the US for individuals with acromegaly who responded to and tolerated treatment with injectable somatostatin receptor ligands (iSRLs). Add-on cabergoline therapy has shown effectiveness in patients previously inadequately controlled with iSRLS.1 The phase 3 MPOWERED trial assessed maintenance of response with OOC compared to iSRLs. Patients receiving OOC and in...